Orlando, USA, 04 March, 2024 – From 3 to 4 February, the inaugural SRS Telesurgery Consensus Conference, hosted by the Society of Robotic Surgery (SRS), took place in Orlando, USA. Throughout this two-day event, nearly 200 attendees from multiple countries came together to discuss breakthroughs in tele-surgery, as well as to share clinical experiences and insights on performing these types of surgeries in the safest possible way.
MicroPort® MedBot™ participated in this conference and showcased the advanced capabilities of Toumai® Laparoscopic Surgical Robot (Toumai®), demonstrating its pivotal role in shaping the future of robotic surgery.
Following its historic achievement at Arab Health 2024 in January, where Toumai® conducted the world's first cross-border 5G remote surgery verification, the robot has continued to break new ground within its field. It successfully accomplished a 5G tele-surgery verification across the Atlantic and a long-distance experiment across the Pacific. These achievements culminated in the world's first "world-tour" of robotic tele-surgery verification.
The transatlantic 5G tele-surgery verification was conducted by Professor Vipul Patel and his team from the Global Robotic Institute at the University of Florida. Professor Vipul Patel, who is the founder and chairman of the SRS, led this surgery verification which covered a distance of over 12,400 kilometers from Orlando to Dubai.
Meanwhile, the intercontinental experiment across the Pacific was performed by Dr. Moschovas and Dr. Breda, involving a right kidney ureteral excision. This surgery spanned approximately 13,000 kilometers from Orlando to Shanghai, becoming the first of its kind, worldwide.
During both surgeries, Toumai® played a crucial role in performing precise and smooth surgical operations, including cutting, dissection, and suturing. Despite spanning ultra-long distances and relying solely on a 5G SIM card, there were no signal interruptions or operational delays. Various surgical actions were executed with near synchrony, completed by clear and well-coordinated communication.
This achievement showcases Toumai®’s adaptability in performing precise, minimally invasive surgical procedures, establishing a solid foundation for the future of cross-border and intercontinental clinical tele-surgeries.
Dr. Chao He, President of MicroPort® MedBot™, was invited to deliver a keynote speech at the conference. He stated that the accomplishment of the first "world-tour" robotic tele-surgery verifications represents a further leap in tele-surgical technology. As of now, Toumai® has achieved a 100% success rate in over 100 cases of 5G tele-surgeries, helping make routine global tele-surgery possible. Its stability, reliability, and safety have been proven across diverse climates and natural settings.
About MicroPort® MedBot™
Founded in 2015, MicroPort® MedBot™ (Shanghai MicroPort MedBot Group Co., Ltd.; HKEX: 02252), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is currently the only surgical robot company in the world with businesses covering six promising subsectors of surgical robots including endoscopy, orthopedics, vascular intervention, natural orifice surgery, percutaneous puncture and medical aesthetics. MicroPort® MedBot™ is committed to meeting the growing demand for cutting-edge robotic surgery by integrating advanced research on robotics, control algorithms, electrical engineering, image-based navigation and precision imaging. MicroPort® MedBot™ provides comprehensive intelligent surgical solutions to lead the advancement of robotic surgery and shape the era of super intelligent surgery so patients everywhere can continue living better and longer lives.
More information is available at www.medbotsurgical.com/en